Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far
Psoriatic arthritis (PsA) is a heterogeneous disease that may develop in up to 30% of patients with psoriasis. PsA mainly involves peripheral joints; however, axial skeleton and entheses can also be involved. PsA is the result of a complex interplay between an individual’s genotype and environmental...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2023-05-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/deucravacitinib-for-the-treatment-of-psoriatic-arthritis-the-evidence-so-far/ |